HEALTHCARE PROVIDER RESOURCES

XARELTO® REPRINTS

REDUCING STROKE RISK IN NONVALVULAR ATRIAL FIBRILLATION (NVAF)

ROCKET AF

Patel MR et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

End-stage Renal Disease (ESRD)

Dias C et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis

DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) TREATMENT AND RISK REDUCTION

EINSTEIN DVT

The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism

EINSTEIN PE

The EINSTEIN PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

Pooled EINSTEIN DVT and PE

Prins MH et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN–DVT and PE randomized studies

EINSTEIN CHOICE

EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism

EINSTEIN cancer subgroups

Prins MH et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE)

VTE PROPHYLAXIS

RECORD1

Eriksson BI et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

RECORD2

Kakkar AK et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

RECORD3

Lassen MR et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

MAGELLAN (subgroup) for acutely ill medical patients

Spyropoulos AC et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study

CORONARY ARTERY DISEASE (CAD) AND PERIPHERAL ARTERY DISEASE (PAD)

COMPASS (CAD/PAD)

Eikelboom JW et al. Rivaroxaban with or without aspirin in stable cardiovascular disease

COMPASS (CAD subgroup)

Connolly SJ et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomized, double-blind, placebo-controlled trial

COMPASS (PAD subgroup)

Anand SS et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial

COMPASS (High-risk subgroup)

Anand SS et al. Rivaroxaban plus aspirin versus aspirin in relation to vascular risk: a post hoc analysis of a randomized, clinical trial

RESOURCES TO HELP YOUR PATIENTS

Janssen CarePath Savings Program

For eligible patients with commercial insurance and an approved chronic condition.

Care4Today® Connect

A helpful medication and appointment tracking and reminder tool designed to empower users to take an active role in their own health care.

OTHER RESOURCES

For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.